Martin Nutraceuticals Cites Articles Blasting the Use of Pharmaceutical Drugs for Arthritis
Posted on: Monday, 22 May 2006, 12:01 CDT
Martin Nutraceuticals Inc. (PINKSHEETS: MNCL) cites a recent edition of Jurist - Legal News and Research in which a jury awarded $9 million in punitive damages recently to a man who blamed VIOXX, finding that manufacturer MERCK & Co. failed to warn about the dangers of its arthritis drug and that prolonged use of the drug was associated with an increased risk of heart attack and stroke and misrepresented those risks. In an unrelated case, Reuters reported that on April 22, a 71-year old man was a victim to VIOXX and awarded $32 million to his family.
Vioxx and other NSAID (Non-Steroidal, Anti Inflammatory Drugs) have come under increasing scrutiny from FDA and Health Canada due to severe risks to the cardiovascular system with prolonged usage of these drugs. NSAIDs have become quite popular due to the fact that over 40 million North Americans suffer from arthritis.
Dr. Martin of Martin Nutraceuticals Inc. suggests there is a safe alternative to these NSAIDs: "Arthrizyme has shown tremendous promise in its anti-inflammatory capabilities without any known side effects."
Arthrizyme is a patented, proprietary blend of systemic oral enzymes that was developed by Martin Nutraceuticals and is now available over the counter in Canada and some parts of the United States.
About Martin Nutraceuticals Inc.
Martin Nutraceuticals Inc. is a company focused on providing a better health and lifestyle through natural products. Martin Nutraceuticals flagship products include Arthrizyme(TM) for general joint pain and Oxygenol(TM) for anti-oxidation and Maximum Slim(TM) for weight control.
Arthrizyme(TM) is a unique blend of systemic enzymes proven to rapidly reduce inflammation in joints and muscles. Arthrizyme(TM) is not limited to anti-inflammatory effects; it also assists the body in the healing process by breaking down fibrin in joints and muscles. Arthrizyme(TM) differs from all other natural arthritis remedies and was designed to work for all types of arthritis and in all joints of the body. Arthrizyme(TM) is fast acting, usually improving symptoms within the first few days.
Safe Harbor Statement
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The risks and uncertainties that may affect the operations, performance development and results of the Company's business include but are not limited to fluctuations in financial results, availability and customer acceptance of our products and services, the impact of competitive products, services and pricing, general market trends and conditions.
Contact Info: Aurora Venture Communications Group http://www.avcg.net/profile/MNCLMNCL@avcg.net 1-(866)-360-1643
SOURCE: Martin Nutraceuticals Inc.
Source: MARKET WIRE
Related Articles
- Anti-aging product improves wrinkles
- ICSA Labs Introduces Formal Testing of Anti-Spam Products
- MitoPharm Targets Baby Boomers, Positions Functional Beverages, Dietary Supplements and Drugs- MitoPharm's Anti-Aging Products for the Baby Boom Generation
- Megola Announces First Anti-Fire Product Shipment
- Targeted Genetics Enhances Inflammatory Arthritis Product Development Platform
- Study of Arthritis Drugs Shows Cancer Risk is Small
- Targeted Genetics Announces Strategic Restructuring to Reduce Expenses and Advance Lead Inflammatory Arthritis Product Candidate
- Court Rules in Merck's Favour Over Vioxx Risks
- Sonus Pharmaceuticals and Schering AG Announce Global Licensing Agreement for Anti-Cancer Product TOCOSOL(R) Paclitaxel
- Schering AG and Sonus Pharmaceuticals Announce Global Licensing Agreement for Anti-Cancer Product TOCOSOL(R) Paclitaxel
User Comments (0)

RSS Feeds